Skip to main content

Table 2 Trends in time from diagnosis to treatment in female cancer patients with different stages

From: Survival outcomes following treatment delays among patients with early-stage female cancers: a nationwide study

Variables

No. (%) of patients

P*

< 1 month (immediate treatment)

1–2 months (intermediate delay)

3–6 months (long delay)

NSCLC

 Stage I

2896 (31.1)

5104 (54.7)

1321 (14.2)

< 0.001

 Stage II

764 (23.2)

2056 (62.4)

476 (14.4)

IBC

 Stage I

23,424 (23.7)

70,132 (70.8)

5470 (5.5)

< 0.001

 Stage II

16,576 (24.7)

46,367 (69.2)

4082 (6.1)

DTC

 Stage I

19,172 (66.6)

7994 (27.8)

1610 (5.6)

0.043

 Stage II

1589 (68.5)

590 (25.4)

141 (6.1)

Colorectal cancer

 Stage I

6791 (60.5)

4099 (36.5)

339 (3.0)

< 0.001

 Stage II

6491 (52.7)

5474 (44.4)

356 (2.9)

Cervical cancer

 Stage I

3369 (51.3)

2652 (40.4)

545 (8.3)

< 0.001

 Stage II

425 (23.9)

1141 (64.1)

214 (12.0)

  1. The tumor stage refers to the TNM stage classification in the 7th edition
  2. NSCLC non-small cell lung cancer, IBC infiltrating breast cancer, DTC differentiated thyroid carcinoma
  3. Bold values indicate statistical significance (p < 0.05)
  4. *Pearson’s Chi-squared test